Bayforest Capital’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$39.4K Sell
352
-592
-63% -$67.8K 0.06% 566
2026
Q2
$108K Sell
944
-600
-39% -$51.6K 0.1% 397
2026
Q1
$129K Buy
+1,544
New +$122K 0.14% 281

Other funds holding KYMR

Bayforest Capital's KYMR Position: Q3 2026 in Review

Bayforest Capital reduced its Kymera Therapeutics (KYMR) stake by 63% in Q3 2026, selling an estimated $67.8K and leaving 352 shares worth $39.4K. The position accounts for 0.06% of the portfolio, ranked #566.

Bayforest Capital first reported a position in KYMR in Q1 2026 and has held it in 3 quarters since. The position peaked at $129K in Q1 2026. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Bayforest Capital held 352 shares of Kymera Therapeutics worth $39.4K as of Q3 2026.
  • Bayforest Capital sold 592 Kymera Therapeutics shares in Q3 2026, an estimated $67.8K.
  • Kymera Therapeutics made up 0.06% of Bayforest Capital's portfolio in Q3 2026, its #566 holding.
  • Bayforest Capital first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Bayforest Capital's Kymera Therapeutics position peaked at $129K in Q1 2026.
  • 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Bayforest Capital's 13F filing for Q3 2026, filed 3 Nov 2026.